SCHEMBL5579110

SCHEMBL5579110

CC(CN1CCC2(CC1)CN(C(=O)c1ccc(F)c(F)c1)c1ccccc12)OC(=O)c1ccc(F)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
MAPT P10636 2/20 0.43
SLC18A3 Q16572 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
NOTUM Q6P988 1/20 0.42
POLB P06746 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
HSD17B10 Q99714 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
P2RY1 P47900 1/20 0.42
PDE4B Q07343 1/20 0.42
USP2 O75604 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578983 0.89 HDAC1 (0.53) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5579002 0.78 HDAC1 (0.59) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578634 0.76 NOTUM (0.48) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578644 0.70 HDAC1 (0.49) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578970 0.70 HDAC1 (0.49) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578473 0.69 OPRM1 (0.44) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL14618844 0.69 HDAC1 (0.50) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578763 0.68 HDAC1 (0.53) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578501 0.67 NOTUM (0.50) HDAC1HDAC6SLC18A3SIGMAR1NOTUM
SCHEMBL5578816 0.67 HDAC1 (0.48) HDAC1HDAC6NOTUMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US claimed
EP-1716148-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF Arena Pharmaceuticals, Inc. (US) 2006-11-02 EP claimed
WO-2005063745-A2 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 WO claimed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL HDAC1 885/4885HDAC6 767/4885MAPT 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.